GLP-1 Agonists Market Size is valued at USD 43.1 billion in 2024 and is predicted to reach USD 260.1 billion by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034.
GLP-1 agonists, known to be beneficial in treating type 2 diabetes, are glucagon-like peptide-1 receptor agonists. The action of GLP-1 RAs is to enhance insulin synthesis and inhibit glucagon secretion by activating GLP-1 receptors. While all GLP-1 RAs have the exact mechanism of action, there are differences in formulation, dose, injection technique, and administration. The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead. These drugs help manage type 2 diabetes by increasing insulin production and decreasing glucagon release, improving blood sugar control and cardiovascular health. GLP-1 agonists have demonstrated potential in managing weight, a crucial motivation. Because type 2 diabetes and obesity are frequently co-occurring, this technique is very helpful in managing both conditions. Because these drugs lead to weight loss, they appeal to patients and doctors. Furthermore, developing new treatments is anticipated to fuel the growth of the GLP-1 receptor agonist market.
However, the market development is hampered by the high-cost criteria for the safety and health of the GLP-1 agonists market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high GLP-1 agonists because GLP-1 agonists are expensive, which can prevent some patients from getting the treatment they need. There may not be extensive use due to this financial obstacle and worries about injections. There may not be extensive use due to this financial obstacle and worries about injections. One potential future hurdle for the growth of the market for glucagon-like peptide 1 (GLP-1) agonists is the availability of suitable insurance. As a result of COVID-19-related travel restrictions and lockdowns, the worldwide supply chain for GLP-1 receptor agonists was disrupted. Because of this, the healthcare business was hit hard by the COVID-19 pandemic, which disrupted the supply chain and compromised processes ranging from ingredient procurement to final delivery.
The GLP-1 agonists market is segmented based on product, application, route of administration and distribution channel. As per the Product, the market includes Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other Products. Whereas, by Application, the market is divided into Type 2 Diabetes Mellitus, and Obesity. Acccording to the Route of Administration, the market is segmented into Parenteral, and Oral. Distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies.
Retail pharmacies make up the bulk of GLP-1 agonists usage because participating in retail pharmacies in clinical trials provides more individualized patient care. As the initial point of contact for many patients seeking medical assistance, retail pharmacists can be crucial in identifying individuals suited for clinical trials, particularly in nations like the US, Germany, the UK, China, and India.
The North American GLP-1 agonists market is expected to register the highest market share in revenue in the near future. The area has a well-developed healthcare infrastructure, major actors are present, the disease prevalence is high, and investments in research and development for novel medications to treat diabetes and obesity are expanding. In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common. With more generic pharmaceuticals hitting the market, the glucagon-like peptide 1 (GLP-1) agonists market is expected to develop in the region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 43.1 Bn |
|
Revenue Forecast In 2034 |
USD 260.1 Bn |
|
Growth Rate CAGR |
CAGR of 19.9% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Application, Route Of Administration, Molecule, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; Japan; South Korea; Southeast Asia |
|
Competitive Landscape |
Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Twist Bioscience Corporation |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GLP-1 Agonists Market Snapshot
Chapter 4. Global GLP-1 Agonists Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global GLP-1 Agonists Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on GLP-1 AGONISTS MARKET Industry Trends
Chapter 5. GLP-1 Agonists Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Ozempic
5.2.2. Trulicity
5.2.3. Mounjaro
5.2.4. Wegovy
5.2.5. Rybelsus
5.2.6. Saxenda
5.2.7. Victoza
5.2.8. Zepbound
5.2.9. Other Products
Chapter 6. GLP-1 Agonists Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis
6.1. Market Share by Route of Administration, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
6.2.1. Parenteral
6.2.2. Oral
Chapter 7. GLP-1 Agonists Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Type 2 Diabetes Mellitus
7.2.2. Obesity
Chapter 8. GLP-1 Agonists Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. GLP-1 Agonists Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global GLP-1 Agonists Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021- 2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021- 2034
9.2.3. North America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021- 2034
9.2.4. North America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021- 2034
9.2.5. North America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021- 2034
9.3. Europe
9.3.1. Europe GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021- 2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021- 2034
9.3.3. Europe GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021- 2034
9.3.4. Europe GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021- 2034
9.3.5. Europe GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021- 2034
9.4. Asia Pacific
9.4.1. Asia Pacific GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021- 2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021- 2034
9.4.3. Asia Pacific GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021- 2034
9.4.4. Asia Pacific GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts By Application, 2021- 2034
9.4.5. Asia Pacific GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021- 2034
9.5. Latin America
9.5.1. Latin America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021- 2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021- 2034
9.5.3. Latin America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021- 2034
9.5.4. Latin America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021- 2034
9.5.5. Latin America GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021- 2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by country, 2021- 2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021- 2034
9.6.3. Middle East & Africa GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021- 2034
9.6.4. Middle East & Africa GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021- 2034
9.6.5. Middle East & Africa GLP-1 Agonists Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021- 2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Eli Lilly and Company
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Sanofi
10.2.3. AstraZeneca
10.2.4. Novo Nordisk
10.2.5. Boehringer Ingelheim
10.2.6. Twist Bioscience Corporation
GLP-1 Receptor Agonist by Product
GLP-1 Receptor Agonist by Application
GLP-1 Receptor Agonist by Route of Administration
GLP-1 Receptor Agonist by Distribution Channel
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
